Insider selling
Traded Nov 12 · filed 2 days laterNot reported under a pre-arranged trading plan
A major shareholder of Exagen sold $509K of Exagen shares. The filing does not indicate a pre-arranged trading plan.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Nov 11, 2026 · Filed Nov 12, 2026
A major shareholder of Exagen paid $373K out of pocket for Exagen shares.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market purchase
Code P — open-market or private purchase
~$372,977
Shares × reported transaction price
$100K–$500K
+2.7%
Purchase shares ÷ estimated pre-transaction holdings, from the filing
First purchase in 0 months
Confirmed open-market purchases by the same insider in the available history
Yes
Compared with 3 earlier confirmed purchases
No other insider purchases within 30 days
Distinct insiders at the same issuer with confirmed open-market purchases
1 day after results of Nov 10, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $5.04 on Nov 11, 2026, 90% above its 52-week low and 48% below its high, after a 38% drop over the previous 30 trading days
52-week range $2.65 (Mar 30, 2026) to $9.59 (Nov 12, 2025), 34% of the way up, from 250 adjusted closes. 30 trading days earlier: $8.13 on Sep 30, 2026. Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
Insider selling
Traded Nov 12 · filed 2 days laterNot reported under a pre-arranged trading plan
A major shareholder of Exagen sold $509K of Exagen shares. The filing does not indicate a pre-arranged trading plan.
Insider selling
Traded Nov 13 · filed 1 day laterNot reported under a pre-arranged trading plan
A major shareholder of Exagen sold $237K of Exagen shares. The filing does not indicate a pre-arranged trading plan.
Fund moves
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Chernett Jorey, 10% owner's past purchases, 90 days after disclosure: 21 buys, median +52.0 pts vs S&P 500, beat it 16 of 21 times. Past results, not a forecast.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.